Literature DB >> 9062670

Modulation of neuronal and glial cell function by adenosine and neuroprotection in vascular dementia.

K A Rudolphi1, P Schubert.   

Abstract

Dementia is one of the major medical challenges in the industrialized countries. An increasing number of demented patients shows ischemic brain lesions. One strategy to treat dementia could be the reinforcement of the multifarious neuroprotective actions of the endogenous cell modulator adenosine. This involves the modulation of neuronal and glial cell functions. Adenosine appears to raise the threshold for the initiation of the pathophysiological cascade of ischemic neuronal death by counteracting ischemic membrane depolarization and the successive disturbance of intracellular Ca2+ homeostasis. When this threshold is overcome, adenosine seems to stimulate astrocyte differentiation and reinforce important protective astrocyte functions, e.g., synthesis and release of neurotrophic factors such as NGF and the clearance of abnormal neurotoxic levels of K+ and glutamate from the extracellular space. Propentofylline, a combined inhibitor of adenosine reuptake and cAMP phosphodiesterases, reinforces the actions of endogenous adenosine and cAMP. One important action of propentofylline is the inhibition of potentially neurotoxic functions of activated microglia (free radical formation and transformation into brain macrophages). Such drugs may help to inhibit the progressive neurodegenerative process in dementia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062670     DOI: 10.1016/s0166-4328(97)86055-x

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  11 in total

Review 1.  The role of glial adenosine receptors in neural resilience and the neurobiology of mood disorders.

Authors:  Dietrich van Calker; Knut Biber
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 2.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 3.  Adenosine receptor signaling in the brain immune system.

Authors:  György Haskó; Pál Pacher; E Sylvester Vizi; Peter Illes
Journal:  Trends Pharmacol Sci       Date:  2005-10       Impact factor: 14.819

4.  Hypoxia/reoxygenation impairs memory formation via adenosine-dependent activation of caspase 1.

Authors:  Gabriel S Chiu; Diptaman Chatterjee; Patrick T Darmody; John P Walsh; Daryl D Meling; Rodney W Johnson; Gregory G Freund
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

5.  High salt culture conditions inhibit serum- and NGF- but not PMA-induced Egr-1 gene transcription in rat C6 glioma cells.

Authors:  Kyoji Morita
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

6.  Sex differences in caffeine neurotoxicity following chronic ethanol exposure and withdrawal.

Authors:  Tracy R Butler; Katherine J Smith; Jennifer N Berry; Lynda J Sharrett-Field; Mark A Prendergast
Journal:  Alcohol Alcohol       Date:  2009-09-16       Impact factor: 2.826

7.  Effect of Kangxin Capsule on the expression of nerve growth factors in parietal lobe of cortex and hippocampus CA1 area of vascular dementia model rats.

Authors:  Jing Cai; Jian Du; Zhen-hua Ge; Fan Zhou; Lin-yin Zhou; Lian-yun Chen
Journal:  Chin J Integr Med       Date:  2006-12       Impact factor: 1.978

8.  Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death.

Authors:  Detlev Boison; Hai-Ying Shen
Journal:  Open Drug Discov J       Date:  2010-01-01

Review 9.  Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brain.

Authors:  Utpal S Bhalala; Raymond C Koehler; Sujatha Kannan
Journal:  Front Pediatr       Date:  2015-01-14       Impact factor: 3.418

Review 10.  Astrocytes as Guardians of Neuronal Excitability: Mechanisms Underlying Epileptogenesis.

Authors:  Quirijn P Verhoog; Linda Holtman; Eleonora Aronica; Erwin A van Vliet
Journal:  Front Neurol       Date:  2020-11-26       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.